Treating latent TB infection prevents TB disease.
For several decades, the United States (with the help of the CDC) has promoted TB prevention and control by treating individuals with LTBI.
Recommended treatment regimens for LTBI are based on the drug susceptibility results of the source case, any coexisting medical conditions, and the potential for drug-drug interactions. A shorter regimen is preferred to achieve treatment compliance, but as mentioned, the regimen chosen depends on several factors. Note that treatment is modified if the patient is known to have been in contact with drug-resistant TB.
Drug(s) most commonly used for treating LTBI include:
- Isoniazid (INH)
- Rifampin (RIF)
- Rifapentine (RPT)
